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ABSTRACT
Breast cancer is the most common diagnosed and deathly cancer in women all over
the world. Besides the conventional cancer therapy, based on the receptors expressed in
breast cancer, hormone therapy targeting estrogen receptors (ER) and progesterone
receptors (PR), and targeted therapy using antibodies or inhibitors targeting human
epidermal growth factor receptor 2 (HER2) are the common and standard treatments for
breast cancer. However, breast cancer is a highly heterogeneous disease. About 15-20% of
breast cancers do not significantly express the three receptors, which are classified as the
triple-negative breast cancer and the most dangerous type of breast cancer because of lack
of effective targets for treatment. New and more targets in breast cancer are an urgent need
in breast cancer treatment. The plasma human prolactin (PRL) was reported positively
associated with the risk of breast cancer, and breast cancer cells can synthesize PRL locally
as an autocrine/paracrine growth factor; the prolactin receptor (PRLR) was found
overexpressed in 80% of human breast cancer cells and tissues, implicating that PRL/PRLR
pathway could be a potential target for breast cancer treatment.
We created a bifunctional fusion protein MICA-G129R to target the PRLR on
breast cancer cells. The G129R is an antagonistic variant of PRL, which binds to PRLR
and induces apoptosis of the target cells instead of promotes their growth. MICA (MHC
class I chain-related protein) is a stress-induced protein and ligand of the activating receptor
NKG2D of natural killer (NK) cells. Advanced cancer cells tend to down-regulate or shed
stress signal proteins, like MICA, to evade immune surveillance and elimination. We
hypothesize that the MICA-G129R fusion protein could bridge the NK cells and PRLR-
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positive breast cancer cells, activate NK cells through the MICA portion and target PRLRpositive breast cancer cells through the G129R portion.
We expressed the MICA-G129R fusion protein and demonstrated that it bound to
human natural killer NK-92 cells and human PRLR-positive breast cancer T-47D cells, and
significantly enhanced the cytotoxicity of NK-92 cells to kill T-47D cells at different
effector/target ratios. The enhancement was only observed by using MICA-G129R fusion
protein but not the MICA only or the G129R only proteins. We compared the T-47D cell
with PRLR-negative HeLa cells and found that HeLa cells were killed more in the coculture with NK-92 cells mediated by MICA-G129R fusion protein. When ectopically
expressing PRLR in HEK293 cells, these originally PRLR-negative cells became sensitive
to the cytotoxicity mediated by MICA-G129R and were lysed. The results indicate that the
MICA-G129R fusion protein mediated cytotoxicity targets PRLR-positive cells. We also
demonstrated that the MICA-G129R protein activated NK cells to release the cytotoxic
molecule granzyme B and cytokine IFN-γ which play key roles in cytotoxicity, and the
cytotoxicity mediated by the MICA-G129R fusion protein triggered apoptosis in target
cells.
In conclusion, the bifunctional fusion protein MICA-G129R bridges NK cells and
PRLR-positive breast cancer cells and enhances the cytotoxicity targeting a new receptor
in breast cancer.
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CHAPTER ONE
LITERATURE REVIEW

1.1 Breast cancer and prolactin
Breast cancer is the most common diagnosed cancer and the leading cause of death
cancer in women all over the world [1]. The American Cancer Society estimates there will
be 276,480 new cases of invasive breast cancer diagnosed in women in 2020 in United
States. The risk that a woman will develop breast cancer during her lifetime is one in eight
and the risk of dying from breast cancer is one in 39 in United States [2].
1.1.1 Treatments for breast cancer
Surgery is always the most common treatment for solid tumor, like breast cancer.
Chemotherapy and radiation therapy are also conventional treatment for breast cancer, but
they have strong side effects and hardly to cure cancer. Chemotherapy usually work
through destroy or inhibit fast-replicating cancer cells but also damage fast-growing normal
cells. Radiation therapy use radiation to destroy tumor cells and is usually used after
surgery or chemotherapy to prevent tumor recurrence. These three treatments are usually
used together as conventional treatment, and less specific targeting to the tumor cells.
Many breast cancers require estrogen for promote growth, express estrogen
receptors (ER) and progesterone receptors (PR) on their cell surface. The hormone therapy
is a type of treatment specific targeting the hormone receptors, either using hormone
antagonists to block the receptors, e.g. tamoxifen [3], or inhibitors to block the production
of estrogen, e.g. anastrozole or letrozole [4]. Another important biomarker and target for
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breast cancer is the human epidermal growth factor receptor 2 (HER2). The overexpression of the HER2 was found strongly associated with the increased disease
recurrence and a poor prognosis of certain aggressive types of breast cancer at about 2030% [5]. Trastuzumab is a humanized monoclonal antibody targeting the HER2 receptor
through activation of antibody-dependent cellular cytotoxicity (ADCC), reduction of
angiogenesis and inducing apoptosis of target cell [6]. Trastuzumab can be used along or
in combination with chemotherapy to treat early stage and metastatic HER2-positive breast
cancer.
Unfortunately, there are many breast cancers are negative to the ER, PR or HER2
receptors, and some are even double or triple negative [7]. The triple-negative breast cancer
(TNBC), encompassing 15% to 20% of all breast cancers, is not sensitive to hormone
therapy or molecular targeted therapy because of lacking targets. TNBC is the most lethal
subtype of breast cancer because of its high heterogeneity, high metastasis frequency, early
relapse after standard chemotherapy, and lack of new and effective treatment options [8,9].
New target in breast cancer is an urgent need not only to treat triple-negative breast cancer
but also to broaden the therapeutic spectrum in breast cancer.
Immune checkpoint inhibitors target checkpoint proteins, e.g. programmed cell
death protein 1 (PD-1) or programmed cell death-ligand 1 (PD-L1), to activate immune
response to destroy cancer cells. So not specific antigens of breast cancer are needed. The
US Food and Drug Administration approved atezolizumab (against PD-L1) in combination
with nab-paclitaxel for treatment of unresectable locally advanced or metastatic triplenegative breast cancer in 2019, giving one more treatment option for this highly aggressive
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disease. There are many problems with immune checkpoint inhibitors in the treatment of
solid tumors like breast cancer, especially triple-negative breast cancer [10].
1.1.2 Prolactin and prolactin receptor
Prolactin (PRL), also known as luteotropin, is a polypeptide hormone belonging to
the growth hormone family and is primarily synthesized and secreted by the lactotrophs in
the anterior pituitary gland [11]. Its major functions include promoting mammary glands
development and growth, and stimulating mammary glands to synthesize and secrete milk
[12].
More and more studies support that PRL contributes to the pathogenesis and
invasion of breast and gynecologic cancers, like ovarian and endometrial cancers [13–15].
Based on the experimental studies and human sample/cohort investigations in the past
decade, the novel views of PRL biology believe: a) high level of circulating PRL is a risk
factor for breast cancer supported by strong epidemiological arguments, b) tumor growth
enhanced by local PRL via autocrine/paracrine mechanisms in both rodent models and
human breast tumors, c) the functional germinal polymorphisms of the PRL receptor
(PRLR) with single amino acid substitution variants exhibiting constitutive activity were
identified in patients with breast tumors, d) engineered human PRL analogs have been used
to down-regulate the effects triggered by local PRL (competitive antagonism) or by the
constitutively active receptor variants (inverse agonism) (Figure 1.1)[16].
PRLR that is structurally homologous with growth hormone receptor, was found
overexpressed in more than 80% of human breast cancer cells and tissues and to contribute
to the development of breast cancer [13,17–19]. The breast cancer cells benefit from both
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the increased PRL and overexpressed PRLR to promote their growth. When PRL binds to
its receptor (PRLR) on cancer cell, it activates the oncogenic signaling pathways such as
JAK2/STAT5 to stimulate the proliferation of cancer cell and promote tumor growth [18].
The PRL/PRLR pathway has been studied for decades because of its etiological
role in breast cancer [20]. There are many potential targets and therapies in this pathway.
The overexpressed PRLR on breast cancer cells is one of the potential therapeutic targets.
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(Bernichtein et al. J. Endocrinol. 2010)
Figure 1.1 Novel views in PRL biology. The four aspects of PRL biology that are
schematized. The classical view is represented in blue, while novel concepts are shown in
red. The latter should be considered as additional to the classical view, and do not substitute
for principles that have been validated over the years. As the main intracellular cascade
downstream the PRLR, STAT5 is just a representative.
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1.1.3 Prolactin mutant G129R
G129R is a created variant of PRL with a single amino acid substitution mutation
at the 129th amino acid, changing from a glycine (G) to an arginine (R), which converts it
to a PRL antagonist (Figure 1.2). G129R still binds to PRLR but does not promote the
growth of cells. Studies found that G129R could effectively inhibit the PRL-induced
JAK/STAT signaling and induce apoptosis in T-47D human breast cancer cells; and
prolonged G129R treatment was able to induce accumulation of redundant autolysosomes
in 3D cancer spheroids resulting in type II programmed cell death, as known as autophagy
[21,22].
The G129R as an antagonist has the great potential to target the PRL/PRLR
pathway in breast cancer treatment. G129R has been well studied as a single agent and also
been fused with other proteins. Endostatin is a well-studied angiogenesis inhibitor which
inhibits the endothelia cells. It was fused with G129R to be a G129R-endostatin fusion
protein which retained the functions of both the two proteins: inhibiting the proliferation
of T-47D and human umbilical vein endothelial cell (HUVEC), and disrupting the
formation of endothelial tube structures [23]. G129R-endostatin was studied in vivo in a
mouse breast cancer model. It exhibited a significantly longer serum half-life than G129R
or endostatin alone, and effective tumor inhibition. G129R was also fused with IL-2 to
activate T lymphocytes in the tumor environment. The G129R-IL-2 was demonstrated
significant inhibitory effects in a breast cancer mouse model [24]. To strengthen the
efficacy of G129R, a truncated form of Pseudomonas exotoxin A was fused with G129R
in a study [25]. The exotoxin was demonstrated not affect the function of G129R in binding
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to PRLR and the inhibition, but inhibit the protein synthesis of the target cells. The target
cell death was found associated with the inhibition of protein synthesis instead of the
caspase mediated apoptosis from G129R.
G129R has also been investigated in combination therapy for breast cancer. For
example, in combination with ER agents tamoxifen G129R could effectively enhance its
inhibition on breast cancer cell lines [21]. By combination with anti-HER2 agents, e.g.
trastuzumab, lapatinib, G129R exhibited a significant additive effect on inhibition of the
breast

cancer

cells

growth

[26,27].

G129R

combination

with

conventional

chemotherapeutics, e.g. cisplatin, paclitaxel, also showed enhanced effects [22,28].

(Chen et al. Clin Cancer Res. 1999)
Figure 1.2 Schematic diagram of mechanism of PRL antagonist. PRL (dotted ovals)
contains four α-helix labeled as I, II, III and IV. PRLR (shaded dark ovals) are the
membrane bound receptor. (A) With the wide type PRL, the two PRLR receptors can form
the functional complex. (B) With an Arg. substitution mutation (G129R) in the third αhelix, the mutated PRL hinders the two receptors to form functional complex.
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1.2 Cancer immunotherapy
Cancer immunotherapy is a type of biological therapy that utilizes immune system
to fight cancer. It is one of the five pillars in cancer treatment with surgery, radiation
therapy, cytotoxic chemotherapy and molecularly targeted therapy. Starting from late
1990s, cancer immunotherapy is becoming the most promising weapon to conquer cancer.
1.2.1 Classification of cancer immunotherapy
Cancer immunotherapies can be classified into five major strategies: tumortargeting monoclonal antibodies (mAbs), immune checkpoint modulators, adoptive cell
transfer, treatment vaccines, and immune system modulators (Figure 1.3) [29]. The tumortargeting monoclonal antibodies are designed to bind to specific antigens on cancer cells
and then induce immune system, like through ADCC, to destroy the cancer cells. Immune
checkpoint inhibitors are drugs, like antibodies, that block immune checkpoints, like
Pembrolizumab targeting the programmed cell death protein 1 (PD-1) receptor. The
immune checkpoints are regulators to prevent immune system from indiscriminately
attacking cells. When they are blocked, the immune cells respond to cancer more strongly.
Adoptive cell transfer is the therapy to transfer immune cells into a patient to boost her/his
immune system to fight cancer. The cells can be from the patient or another donor, can be
T cells, NK cells or other immune cells, and can be raw immune cells or genetically
modified immune cells to enhance their ability to fight cancer. Treatment vaccines are a
therapy to strengthen the body’s natural immune response to cancer. Using lower level
tumor-associated antigens, the treatment vaccines can induce the immune system to
recognize and respond to the antigens and eliminate the cancer cells with the antigens.
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Immune system modulators are some agents that enhance the body’s immune response to
cancer, like cytokines or immune system-stimulating drugs.

Figure 1.3 Schematic diagram of cancer immunotherapy.

Beyond the above classification, one type of design can be used for several
strategies of cancer immunotherapy. For example, bispecific antibodies are a growing class
of immunotherapies using several immunotherapeutic strategies. First, they can be used as
cytotoxic effector cell redirectors. Some bispecific antibodies with one portion engaging
with T-cell receptor can redirect T-cell to cancer cells through their other portion specific
binding to a tumor-associated antigen. Second, some bispecific antibodies act as tumor-
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targeted immunomodulators. Designed to be inactive until binding the tumor-associated
antigen, they locate the tumor first and then stimulate immune responses in the tumor
environment, while minimizing immune activation elsewhere. Third, bispecific antibodies
can be dual immunomodulators which co-stimulate two immunomodulating targets, like
PD-1 and LAG-3 to induce superior tumor immunity [30].
1.2.2 Challenges in cancer immunotherapy
Although many big progresses have been made in immunotherapy like the recent
clinical success in immune checkpoint therapy, there are many challenges in cancer
immunotherapy. The following are several major challenges.
First, the major limitation for cancer immunotherapy is that it is difficult to identify
clinically significant biomarkers. The ideal biomarkers are targetable tumor-specific
antigens that are only expressed in tumor cells. But for most antigens we have are tumorassociated antigens that expressed in both tumor and normal cells. By targeting them, offtarget toxicities are the unavoidable difficult issue that one must be considered [31].
Second, another big obstacle for successful immunotherapy is the heterogeneity of
tumor. Due to the intrinsic tissue diversity of tumor, the accumulation of genetic mutations
in cancer cells, the immune suppression “selection” and many unknown reasons, tumors
tend to have very high heterogeneity. It makes to find specific antigens and choose
therapeutic strategies much difficult and makes drug resistance much easier to be
developed.
Third, lack of functional immune cells or immune system is another big problem
for immunotherapy. Through long time fighting with cancer or treatment with
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chemotherapy and other cytotoxic agents, the immune system of cancer patients may be
impaired and disfunction while immunotherapy relies on the activation of immune system
to attack cancers. For the CAR-T therapy, even getting enough T cells from the patient, it
will also be a big challenge for the patient during the time of preparing the CAR-T. There
are many studies using other resources of immune cells, such as donor allogenic cells,
umbilical cord blood derived or iPSC derived T cells and NK cells [32,33], which may be
the solution after solving the safety issues.
Fourth, there are many immunotherapy-related adverse effects. For example,
cytokine storm is a serious short-term adverse effect. Immunotherapy can trigger the
activation of large numbers of immune cells to release variant cytokines, which in turn
activate more immune cells, resulting in systemic hyper-inflammation, hypotensive shock,
and multi-organ failure and even death [34]. For longer-term effects, immunotherapy has
potential risk to cause autoimmune disease by the induced agents such as the PD-1
inhibitors [35], and possible risks to acquire mutations when transferring autologous or
allogeneic expanded or genetic engineered T cells and NK cells [36].
Last but not least, cancer immunotherapy is very expensive. Take metastatic
melanoma for an example, to use pembrolizumab for one-year per-patient costs of
$145,010 and achieves median progression-free survival (PFS) of 6.3 months; to use
nivolumab for one-year per-patient costs $64,680 and achieves PFS of 5.1 months [37].
Another example is to use CAR-T therapy to treat B-cell acute lymphoblastic leukemia.
When administering tisagenlecleucel (Kymriah; Novartis) including the cost of the drug
($475,000), its administration, and oftentimes inpatient care for toxic side-effects, hospitals
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may charge as much as $1.5 million or more, to avoid losing money, according to Richard
T. Maziarz, MD, professor of medicine at Oregon Health & Science University’s Knight
Cancer Institute in 2019.
Although there are many challenges, cancer immunotherapy is still a promising
innovative treatment for cancer. Through continuously exploring and studying, cancer
immunotherapy complemented with other strategies can become a precise, personalized
and powerful tool to treat most types of cancer. The author believes that immunotherapy is
the most promising hope for conquering cancer.
1.3 Natural Killer Cell
Natural killer (NK) cells are one type of innate lymphocytes. The term “natural”
referred to their natural existence in body and “killer” to their spontaneous killing
malignant cells without immunization. NK cells constitute about 5% to 20% of human
blood lymphocytes and play an importance role in tumor immunosurveillance [38,39].
1.3.1

Development stages and “education”
NK cells were believed to develop in the bone marrow before, but new findings

support that they also develop and mature in secondary lymphoid tissues, such as tonsils,
spleen and lymph nodes [40]. In humans, the development of NK cells can be demarcated
as a total of six developmental stages based on the surface markers on NK cells (Figure
1.6). Expression of CD244 (2B4) starts the developmental process as Stage 1 (pre-NK cell
precursors). CD3ε−CD7+CD127+ define the Stage 2a, CD122 and the low levels of
interleukin (IL)-1R1 expressions define Stage 2b (NK cell progenitors). A higher
expression of IL-1R1 define the Stage 3 as the immature NK cell (iNK), and the
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expressions of NKG2D, CD335 (NKP46), CD337 (NKP30), and CD161 (NK1.1) are
initiated. Stage 4a cells express NKG2D, CD335, CD337, CD161 abundant amounts of
CD56 (CD56bright) but no NKP80. In Stage 4b, NK cells express NKP80 and maintain the
CD56bright. Stage 4 is the entry of iNK cells into mature NK cells. Expression of CD16
(FcγRIIIA) and downregulation of CD56bright to CD56dim define Stage 5. The maturation
Stage 6 is defined by the expression of CD57. The “adaptive” or “antigen-experienced”
NK cells are identified by the high levels of NKG2C [39].

(Abel et al. Front Immunol. 2018)
Figure 1.4 A common schema of human NK cell development in the bone marrow and
lymph nodes.

NK cells distinguish “self” from “non-self” through inhibitory receptors by
interaction with self-major histocompatibility complex (MHC) class I expressed in
virtually all nucleated cells to prevent overkilling of health cells. The cells loss of MHC
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class I, like viral infected cells or early stages of malignant transformed cells, will be
detected and killed by NK cells. This is the “missing-self” hypothesis. So, the expression
of the inhibitory receptors are the key for the self-tolerance of NK cells, but a small group
of NK cells were found without expression of self-reactive inhibitory receptors and still
self-tolerant [41]. Therefore, “licensing” model and “arming-disarming” models were
proposed to supplement the NK cell education process, such as. These models basically
suggest that the inhibitory receptors targeting MHC class I protein also play a role in the
acquisition of functional competence during NK cell development besides regulation of
NK cell activation. Overall, the “education” of NK cells has not been clearly known.
1.3.2 NK cell Receptors
NK cells are defined by the differential expression of lineage-specific surface
markers, like positive to CD56 (neural cell adhesion molecule (NCAM)), and negative to
CD3/14/19 [42]. About 90% of NK cells are CD56dim and most of them express high
density of CD16. They carry out cytotoxicity in early innate immunity to against viral
infected or malignant transformed cells through ADCC or other activating receptors to
secrete IFN-γ, perforin and granzymes. They also induce apoptosis of target cells through
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or Fas ligand
(FasL). The other 10% of NK cells with CD56bright play a role in late inflammatory response
by releasing IFN-γ, TNF-α, granulocyte-macrophage colony-stimulating factor (G-CSF)
and IL3 to prime adaptive immunity.
There are many similarities between NK cells and T cells in their functions and
phenotypes, but as their development in the body are quite different, their activation is very
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different when detecting infected or malignant cells. T cells somatically rearrange their T
cell receptors to recognize foreign antigen to be activated, while NK cells do not rearrange
receptors but are regulated by many germline-encoded activating and inhibitory receptors
[43]. The balance between the activating and inhibitory signals determines the status of
NK cells, and NK cells can target and eliminate tumors directly which is mainly governed
by the integration of signals from activation and inhibitory receptors [44]. The major
families of NK cell receptors are summarized in Table 1.1 [45].
The Natural cytotoxic receptor (NCR) family including NKp30, NKp46 and
NKp44, does not have the signaling motives in their cytoplasmatic domains, except NKp44
containing an immunoreceptor tyrosine-based inhibition motif (ITIM). NCRs associate
with the immunoreceptor tyrosine-based activation motives (ITAM)-containing adapter
transmembrane proteins, e.g. CD3-ζ and FcεRIγ. NCRs involves in antivirus cytotoxicity
and mediates the production of proinflammatory cytokines [46], and also play roles in
antitumor cytotoxicity and tumor immune evasion. B7-H6, MLL5 were two tumorassociated ligands for NCRs [47,48]. Down-regulation of some NCRs has been reported in
many malignancies, such as decreased NKp30 in breast, hepatocellular cancer (HCC),
chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML); decreased
NKp46 in melanoma, pancreatic, gastric, cervical cancer, and AML; decrease NKp44 in
many solid and hematological malignancies [45].
The NK group 2 calcium‐dependent lectin‐like receptor (NKG2) family including
NKG2D homodimer receptors and CD94/NKG2-A/C/E/F/H heterodimer receptors,
interacts with nonclassical MHC class I molecules for activating or inhibitory functions.
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NKG2D is a very important activating receptor on NK cells and will be discussed
separately in a following section. CD94/NKG2A is an inhibitory receptor with an ITIM
while CD94/NKG2C is activating receptors through association with adaptor proteins, and
both participate the antitumor response of NK cells. Increasing of NKG2A expression was
reported associated with poor prognosis in breast cancer and colorectal carcinoma [49,50].
On the other hand, decreased expression of NKG2C was found to lead to dysfunction of
NK cell in AML [51].
The killer cell immunoglobulin like receptor (KIR) family regulates NK cells
through interacting with MHC class I molecules. KIRs detect the loss of MHC class I
expression on cells, which happens in viral infected cells or transformed cells. This allows
NK cells to distinguish unhealthy cells from health cells. Most of KIRs are inhibitory
receptors and signal through the ITIM in their cytoplasmic domain to dampen NK cell
activation. There is also few activating KIRs. Increased inhibitory KIRs has been found
associated with NK cell function and immunosuppression in many cancers, such as breast
cancer [52] and lung cancer [53].
The nectin-binding adhesion molecules family regulates NK cells through binding
nectin proteins. For example, DNAX accessory molecule 1 (DNAM1) as activating receptor,
binds to PVR and nectin-2 on target cells to mediate the stable interaction of NK cells and
target cells [54]. Down regulation of DNAM1 could inhibit NK cell function while
upregulation of its ligands on tumor cells led to increased sensitivity to the lysis mediated by
NK cells [55,56]. Two inhibitory receptors in this family, T cell-activated increased late
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expression (TACTILE) and T-cell immunoglobulin and ITIM domain (TIGIT) are also
immune checkpoints and can be investigated as immunotherapeutic targets [57].

CD16 is one of the most important NK cell cytotoxic receptors and mediates
antibody-dependent cell mediated cytotoxicity (ADCC). It associates with FcεRIγ or CD3ζ
either as homodimers or heterodimers, both containing ITAM motifs. Through CD16, NK
cells are activated to release cytotoxic granules, activate TNF-α family death receptors, and
release proinflammatory cytokine, such as IFN-γ and TNF-α, leading to apoptosis of the
target cell and induce adaptive immune responses. CD16 promoting strong effector
functions without requiring synergy through costimulatory receptors, has great potential in
immunotherapy. Decreasing of CD16 has also been found in numerous malignancies such
as breast cancer, multiple myeloma and melanoma [58,59].
There are many other receptors on NK cells for the cytokines that highly influence
the function of NK cells, such as IL-2 receptor for IL-2 to increase NKG2D expression
[60], IL-15 receptor for IL-15 to promote NK cell differentiation and proliferation [61], IL18 receptor for IL-18 to stimulate IFN-γ production [62] and IL-21 receptor for IL-21 to
enhance NK cell maturation [63].
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Table 1.1 NK cell activating and inhibitory receptors.

(Konjević et al. InTech. 2017)
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1.3.3 Activating receptor NKG2D and its ligands
NKG2D (natural killer group 2, member D) encoded by the gene KLRK1 is an
activating receptor on NK cells, and also found on CD8+ cytotoxic T cells, some NKT
cells, some γδ T cells, and a small subset of CD4+ cytotoxic T cells [64].
In humans, two NKG2D associates with four hematopoietic cell signal transducer
adaptor proteins, DAP10, by ionic interaction in their transmembrane segments to form a
hexametric receptor complex. The two NKG2D ectodomains in the hexametric receptor
complex for binding ligands. When the ligands bind to them, the receptor complex activates
NK cells through the PI3K (phosphatidylinositol-3 kinase) and Grb2-Vav1 (growth factor
receptor-bound protein 2, vav guanine nucleotide exchange factor 1) signaling pathways
to promote Ca2+ influx, actin cytoskeleton reorganization and microtubule polarization,
resulting in the releasing of the contents in the granules of NK cells to induce the apoptosis
of target cells. Granzymes and perforin are the major toxins in the granules. Perforin forms
pores on the membrane of the target cells and granzymes diffuse through the pores into the
target cells and trigger the mitochondria-mediated apoptosis [65]. At the same time,
cytokines, like IFN-γ, are also secreted by activated NK cells to recruit and stimulate other
immune cells, like macrophages and T cells, to destroy the target cells.
NKG2D is a quite conserved receptor but its ligands are very diverse. The NKG2D
ligands are all structurally like the major histocompatibility complex (MHC) class I
proteins that are highly polymorphic. They include MICA and MICB that are the two most
extensively studied NKG2D ligands in humans; and UL16 binding proteins (ULBPs) in
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both human and mouse; murine UL16-binding protein-like transcript 1 (MULT1), retinoic
acid early transcript 1 (Rae1) and histocompatibility antigen 60 (H60) in mouse [64].
The ligands of NKG2D are induced to express in the cells under the stress of virus
infection or malignant transformation, therefore they are called “induced-self” ligands, and
rarely express in healthy cells. By recognizing these ligands, NK cells detect and eliminate
the virus infected or malignant transformed cells in immune surveillance. On the other
hand, advanced tumor cells tend to down-regulate or shed off the NKG2D ligands to escape
the immune surveillance and elimination. NKG2D and its ligands play critical roles in
cancer immune surveillance, which is one of the most significant findings in the fight
against cancer in recent decades.
There are a lot of studies about NKG2D/NKG2D ligands-related cancer
immunotherapeutic strategies [64]. Firstly, the NKG2D ligands can be up-regulation to
enhance the activation of NK cells. The ligands can be stimulated by many drugs, such as
all-trans retinoic acid (ATRA), trichostatin A, vitamin D3; some histone deacetylase
inhibitors; some viral proteins, like E1A in adenovirus; and some chemotherapeutic agents
or radiotherapies as a side-effect by causing DNA damage. Secondly, NKG2D can be upregulated in NK cells to enhance their ability in immune surveillance by the gamma-chain
containing cytokines, such as interleukin (IL)-2 , IL-7, IL-12, and IL-15; IL-15
superagonist mutant (N72D) alone or associated with a dimeric IL-15 receptor α/Fc fusion
protein; and other cytokines, like IL-21, interferon (IFN)-γ, and transforming growth factor
(TGF)-β. Lastly but not least, NKG2D and NKG2D ligands have been widely used as part
of multi-functional fusion proteins in the studies of cancer immunotherapy (Figure 1.4).
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(Ding et al. Int. J. Mol. Sci. 2018)
Figure 1.5 Schematic diagram of NKG2D/NKG2D ligand-related fusion protein
strategies in cancer immunotherapy. Fc, fragment crystallizable region of an antibody;
ADCC, antibody-dependent cell-mediated cytotoxicity; CD3, cluster of differentiation 3;
DAP10, hematopoietic cell signal transducer; PI3K, phosphatidylinositol-3 kinase; Grb2,
growth factor receptor-bound protein 2; Vav1, vav guanine nucleotide exchange factor 1;
CAR, chimeric antigen receptors.
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In the fusion protein strategies with NKG2D, NKG2D can be fused with antibodies
to use the NKG2D portion to target NKG2D ligand-bearing tumor cells, and use the Fc
portion of the antibody to induce ADCC of NK cells or use the antibody to activate immune
cells, for example anti-CD3 to activate T cells; NKG2D can fused with cytokines, like IL2, IL-15 and IL-21 to simultaneously promote immune cells’ function and induce more
anti-tumor responses; NKG2D can also be constructed to be CARs with CD3ζ, CD28 or
4-1BB and used in cell therapy. In the fusion protein strategies with NKG2D ligands, the
ligands can be fused with antibodies, such as antibodies targeting HER2, CD20 or VEGFR
(antigen vascular endothelial growth factor receptor), to simultaneously activate other
immune responses; NKG2D ligands can be fused with cytokines, like IL-2 or IL-12, to
activate immune cells; NKG2D ligands can also be fused with death receptors, for example
Fas, to induce the target cell death at the same time (Table 1.1) [64].
In a recent study, the extracellular domain of NKG2D as targeting moiety fused to
the Fab fragments of anti-CD3 or anti-CD16 antibodies for activating the reactivity of T
cells or NK cells for immunotherapy of AML. The NKG2D-anti-CD3 mediated overall
more potent effects which manifested after longer times, and the NKG2D-anti-CD16
bound to CD16 on NK cells with high affinity and induced superior activation,
degranulation, IFN-γ production and lysis of acute myeloid leukemia (AML) cell lines and
patient AML cells in short term application [66].
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Table 1.2 Fusion proteins of NKG2D/NKG2DLs in cancer immunotherapy
Strategy

NKG2DL +
Antibody

NKG2DL +
Cytokine
NKG2DL +
Fas
NKG2D +
Antibody
NKG2D +
Cytokine
NKG2D
CARs

Fusion protein
H60-TNT3
Rae1β-TNT3
MICAE-Fc (conjugate with Fab)
ULBP2-BB4
anti-HER2 IgG3-Rae1β
ULBP2-anti-PSMA scFv
MICAE-7D8
ULBP2E-7D8
ULBP2-anti-CEA
mAb04-MICAE
anti-VEGFR2 scFv-MICAE
rG7S-MICAE
MULT1E-IL-12
MICAE-IL-12
OMCP-mutIL-2

Target/Pathway
UNA
UNA
CEA/HER2/CD20
CD138
HER2
PSMA
CD20
CD20
CEA
VEGFR
VEGFR
CD24
IL-12R
IL-12R
IL-2R

Malignancy
YAC-1
CT-26, LLC
CC, BC, OC, Raji
MM
MC
PC
CLL, MZL, MCL
CLL, MZL, MCL
CC
BC
HUVEC, K562, MDA-MB-435
HCC
TC-1
A549
LLC, YAC-1

References
[67]
[67]
[68]
[69]
[70]
[71]
[72]
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]

MULT1E-FasTI

Fas

TC-1

[80,81]

NKG2DE-Fc
Dap10-Fc-NKG2DE
anti-CD3 scFv-NKG2DE
NKG2DE-Fc-IL-2
dsNKG2DE-IL-15
dsNKG2DE-IL-21
NKG2D-CD3ζI
NKG2DE-CD28-CD3ζI
NKG2DE-4-1BB-CD3ζI
DAP10-NKG2DE-CD3ζI

ADCC
–
CD3
IL-2R
IL-15R
IL-21R
TCR
TCR
TCR/CD137
TCR

BC
RMA/RG, P815
RMA/RG, P815, ID8, MC-38
TC-1
CC
CT-26
MM, OC, Lymphoma, BC, etc.
ESFT, 4T1.2
OC
Osteosarcoma, 4T1.2

[82,83]
[84]
[85]
[86]
[87]
[88]
[89–101]
[92,102]
[103]
[92,104]

Subscript formatted E, T and I indicate extracellular domain, transmembrane domain, and
intercellular domain, respectively. The NKG2D/NKG2DLs pathway was not included in
the Target/Pathway column. UNA, universal nuclear antigen; LLC, Lewis lung carcinoma;
CEA, carcinoembryonic antigen; HER2, human epidermal growth factor receptor 2; CC,
colon carcinoma; BC, breast carcinoma; OC, ovarian carcinoma; MM, multiple myeloma;
MC, mammary carcinoma; PSMA, prostate carcinoma membrane; PC, prostate carcinoma;
CLL, chronic lymphocytic leukemia; MZL, marginal zone lymphoma; MCL, mantle cell
lymphoma; VEGFR, antigen vascular endothelial growth factor receptor; HUVEC, human
umbilical vein endothelial cell; HCC, hepatocellular carcinoma; TCR, T cell receptors;
ESFT, Ewing’s sarcoma family of tumors.

(Ding et al. Int. J. Mol. Sci. 2018)
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1.4 MICA in immunotherapy
1.4.1 MICA
The major histocompatibility complex (MHC) region on chromosome 6 contains a
group of polymorphic genes that play critical roles in protection against pathogens and
tumorigenesis in our immune system. The MHC gene family is classified into three
subgroups: MHC class I, II and III. The MHC class I and II genes encode antigenpresenting proteins to bind and present short peptides derived from non-self (like bacteria
in infection) or self (like autoantigens) to trigger immune responses. Class III genes encode
molecules involved various immune processes, like components and cytokines [105]. In
1994, a new group of genes related to MHC class I genes were identified on chromosome
6 and named MHC class I chain-related genes (MIC) [106,107]. MICA is a very important
member of this family.
MICA, like MHC class I proteins, also has three extracellular domains α1, α2 and
α3, but unlike classical class I protein, MICA does not bind β2-microglobulin. It is a
membrane-bound glycoprotein and a critical ligand to NKG2D, the activating receptor on
NK cells, γδ T and CD8(+) αβ T cells. MICA binds to NKG2D homodimer with its α1 and
α2 domains (Figure 1.5). MICA acts as a stress signal protein which is absent from most
healthy cells but induced in cells under stress, such as viral and bacterial infection
[108,109], heat shock [110], DNA damages response [111] and malignant transformation
[112]. So, the NKG2D-bearing immune cells can identify and remove these stressed cells.
This is one if the effective mechanism of immunosurveillance.
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MICA was found expressed on many primary tumor isolates from carcinoma (lung,
breast, kidney, prostate, ovary, and colon), melanoma, and some primary leukemia cells
[113]; almost all primary glioma isolates [114]; about 75% of primary cutaneous melanoma
isolates and 50% of metastatic melanoma lesions [115].

Figure 1.6 Crystal structure of MICA in complex with NKG2D homodimer. Protein
Data Bank: 1HYR. The extracellular domain of NKG2D is indicated in orange or green.
The extracellular domain of MICA is indicated in purple.
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1.4.2 Shedding of MICA
It was reported that the advanced tumors tend to down-regulated or shed NKG2D
ligands to evade immune elimination [116]. The shed MICA is released as soluble MICA
(sMICA) into the circulation. sMICA was found significantly elevated in the sera of
patients with leukemia [117,118], colorectal cancer [119], prostate cancer [120], lung
cancer, ovarian cancer, prostate cancer, breast cancer [121], pancreatic cancer [122,123],
oral squamous cell cancer [124,125] and hepatocellular cancer [126]. The elevated sMICA
levels were found significantly correlated with cancer stage and metastasis [121,127].
The shedding of MICA was found to be mediated by matrix metalloproteinases
through proteolytic cleavage in the stalk of the MICA ectodomain. Two members of the “a
disintegrin and metalloproteinase” (ADAM) family, ADAM10 and ADAM17 were
reported critically involved in the proteolytic release of soluble MICA facilitating the
tumor immune escape (Figure 1.6) [128,129].
The shedding of MICA by advanced tumors not only directly reduce the MICA
signal protein on tumor cells but also results in systemic downregulation of NKG2D on
NK and CD8+ T cells, both obstructing the recognition of tumor cells and helping the
evasion of NKG2D-mediated immune surveillance [130]. But there are many other factors
also involved in the regulation. For example, to block TGF-β was reported be able to
increase NKG2D expression regardless of the levels of sMICA in sera [131]. Cytokines,
like IL-2 and IL-18, were also found could overcome the inhibition to from sMICA
NKG2D [132].

26

(Waldhauer et. al. Cancer Res. 2008)
Figure 1.7 MICA is cleaved in its stalk region. (A) Sequence of the MICA stalk
connecting the α3 and the transmembrane domain (TM) where vertical arrows indicate
COOH termini of shed sMICA as determined by MS (top line). Bottom lines, mutant
MICA sequences with deletions (1D to 3D) or alanine substitutions (1M to 6M),
respectively, transfected into C1R cells. (B) Soluble MICA (sMICA) in supernatants of
C1R cells stably expressing MICA mutants was determined after 16 h of cultivation using
a sMICA-specific sandwich ELISA. No sMICA was detectable in supernatants of C1Rneo and C1R-Mut 3D transfectants (data not shown).

1.4.3 MICA Related Immunotherapy Strategies
As MICA is the signal protein on tumor cells to activate NK cells, to overexpress
MICA to strength the signal is a straightforward strategy. Methylselenol (CH3SeH) is a
selenium compound and known for its ability to selectively kill transformed cells by
promoting formation of reactive oxygen species, causing DNA damage, inducing apoptosis
and inhibiting angiogenesis. It was reported that methylselenol significantly induces MICA
expression on cell surface, so could improve NKG2D-based immune therapy [133].
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MICA was also fused into bifunctional fusion protein for targeting NKG2D and
activate NK cells. For instance, MICA was fused with the human CD20 single-chain
fragment variable derived from antibody 7D8. The fusion protein activated NK cells to
lyse CD-20 expressing target cells and simultaneously enhanced the ADCC activity
mediated by full length antibodies [72]. Antibody mAb04 against VEGFR2 (vascular
endothelial growth factor receptor 2) was also fused with MICA. The fusion protein
maintained the anti-angiogenic and antineoplastic activities of mAb04 and simultaneously
enhanced immunosurveillance of NK cells. In human breast tumor-bearing nude mice, the
fusion protein demonstrated significant anti-tumor efficacy, even stronger than the
combination therapy of mAb04 and chemotherapy medication Docetaxel, or another antiVSVG antibody bevacizumab and Docetaxel, which pointed up the immunostimulatory
effect of MICA [74]. MICA was also fused with rG7S a single-chain antibody fragment
targeting the tumor-associated antigen cluster of differentiation 24 (CD24) [76] or fused
with the Fc region of antibody and then chemically conjugated with the Fab regions of
other antibodies, e.g. anti-CEA against carcinoembryonic antigen, trastuzumab against
HER2, and rituximab against CD20 [68]. All of them successfully induced NK cellmediated target cell lysis. In a previous study of our lab, Tietje et al. fused MICA to human
IL-12 which is a cytokine activating NK cells and enhancing the cytotoxic activity of NK
cells. This fusion protein primed NK cells much more effectively compared to either IL12 or MICA alone, and increased the proliferation and IFN-γ production of human
peripheral blood mononuclear cells (PBMCs) [78].
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CHAPTER TWO
HYPOTHESIS AND OBJECTIVES

2.1 Hypothesis
In this project, a bifunctional fusion protein was created with the extracellular
domain of MICA, a stress-induced protein and ligand of the activating receptor NKG2D of
NK cells, and G129R, an antagonistic variant of PRL. We hypothesize that the fusion
protein will bridge the PRLR-positive breast cancer cells and NK cells through the
engagement of G129R to PRLR on breast cancer cells and MICA to NKG2D on NK cells,
and at the same time the fusion protein will activate NK cells and induce cytotoxicity to
kill breast cancer cells. This MICA-G129R fusion protein represents a new approach for
the development of breast cancer specific immunotherapy.
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Figure 2.1 Schematic diagram of the hypothesis.
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2.2 Objectives
We have three objectives in this study.
1) To express the MICA-G129R fusion protein.
We will design the fusion protein in consideration of its structure, MICA shedding,
secretion, detection and purification. We will construct the MICA-G129R gene in
an expression vector, transfect it into mammalian cells, detect its expression and
secretion, confirm its integrity, and purify it from the media.
2) To investigate if MICA-G129R induces cytotoxicity.
We will first investigate if MICA-G129R can induce cytotoxicity in the co-culture
of NK cells and T-47D cells (a PRLR-positive breast cancer cell line) at different
target/effector ratios. Then investigate the MICA-G129R mediated cytotoxicity in
many conditions: with MICA-G129R, with MICA alone, with G129R along, with
PRLR-negative cells and with PRLR ectopically expressed cells.
3) To investigate if MICA-G129R activates NK cells.
We will investigate the binding of MICA-G129R to NK cells and T-47D cells, the
releasing of IFN-γ and granzymes from NK cells, and the apoptosis of target cells
in the cytotoxicity mediated by MICA-G129R.
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CHAPTER THREE
MATERIALS AND METHODS

Construction of vectors
The MICA extracellular domain sequence (c.-23 to c.894) was cloned from the
pcDNA3.1_MICA/IL-12 vector constructed previously created by our lab [78] with the
primer 1_F and primer1_R that contained a (GGGS)×3 linker (Table 2). The MICA
sequence was inserted in to the vector pcDNA3.1/Zeo(+) (ThermoFisher Scientific,
V86020). The G129R sequence (c.85 to c.681) without the signal peptide (p.1-28) and stop
codon, was cloned from the pCR3.1_G129R plasmid provided by Dr. Wen Y. Chen as a
gift with the primer 2_F and primer 2_R, and inserted into the vector pLenti7.3
(ThermoFisher Scientific, K5325-20). Then the sequences of G129R with the V5 tag and
the 6×His (polyhistidine) tag in the pLenti7.3 vector were cloned with the primer 3_F and
primer 3_R. A stop codon was added after the 6×His tag sequence in the primer 3_R. This
fragment was inserted into the 3’ end of MICA of the pcDNA3.1/Zeo(+) vector. The
sequences of the fusion gene MICA-G129R, the V5-tag and the 6×His tag were confirmed
by DNA sequencing.
The MICA extracellular domain sequence (c.-23 to c.894) was cloned and inserted
into another pcDNA3.1/Zeo(+) vector using the primer 4_F and primer 4_R as the
pcDNA3.1_MICA control vector. A stop codon was included in the primer 4_R. The
G129R sequence (c.1 to c.684) with the signal peptide (p.1-28) and the stop codon was
directly cut from the pCR3.1_G129R plasmid using the restriction enzymes BamHI and
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XhoI, and inserted into the pcDNA3.1/Zeo(+) vector as the pcDNA3.1_G129R control
vector.
The entire cDNA sequence of PRLR was cloned from a PRLR cDNA plasmid (Sino
Biological, HG10278-UT) with the primer 5_F and primer 5_R, and inserted into the vector
pcDNA3.1(+) (ThermoFisher Scientific, V790-20).
Table 3.1 Primers used in the cloning
Sequence

Name
Primer1_F

CCCaagcttGAGAGGGTGGCGACGTCGGGG

Primer1_R

TCTggatccAGAACCACCACCAGAACCACCACCAGAACCACCCCCAGAGGGCAC

Primer2_F

CCggatccTTGCCCATCTGTCCCGG

Primer2_R

CGCctcgagGCAGTTGTTGTTGTGGATGATT

Primer3_F

CCggatccTTGCCCATCTGTCCCGG

Primer3_R

TGAgcggccgcTCAATGATGATGATGATGATGACCGGTACGCGTAGAATC

Primer4_F

CCCaagcttGAGAGGGTGGCGACGTCGGGG

Primer4_R

TGAgcggccgcTCACCCAGAGGGCACAGGGTG

Primer5_F

tggCTTAAGccaccATGGAGGAAAATGTGGCATCTGC

Primer5_R

AAGActcgagTCAGTGAAAGGAGTGTGTAAAACATGC

Cell culture
The T-47D, NK-92, HEK293 and HeLa cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA) and cultured following the methods
recommended by ATCC at 37℃ in a 5% CO2 humidified incubator. All the media, fetal
bovine serum and donor horse serum were purchased from Corning (NY, USA); other
supplements were from ThermoFisher Scientific (MA, USA). Two hundred units per ml of
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recombinant human IL-2 from PeproTech (NJ, USA, Cat. 200-02) was used in NK-92 cell
culture.
Transfection
All the cell transfections were carried out using Lipofectamine 2000 (ThermoFisher
Scientific) following the instruction of the manufacturer. To obtain stable clones, the
transfected cells were cultured in the selecting media containing 400 μg/ml of zeocin
(InvivoGen, ant-zn-5) for pcDNA3.1/Zeo(+) vector transfection or 500 μg/ml of Geneticin
(ThermoFisher, 10131035) for pcDNA3.1(+) vector transfection. The cell clones left after
selection were carefully transferred to new flasks to expansion and tests.
Conditioned media
To test the production of MICA-G129R fusion protein in the conditioned media, 4
× 106 cells of HEK293 stable clone with MICA-G129R vector were cultured in a T75 flask
with 12 ml of culture media without zeocin. A 50 μL sample of the conditioned media was
collected from the culture every 24 hours from day 1 to day 5. The media were centrifuged
at 1000 g for 15 minutes, then 40 μl of supernatant was collected and froze at -80℃ until
examination. Forty μl of fresh medium was used as the conditioned medium of day 0. For
all the other conditioned media used in this study, 4 × 106 cells of HEK293 without
transfection (for control conditioned media) or the stable clone with MICA-G129R vector
(for MICA-G129R conditioned media), MICA vector (for MICA conditioned media) or
G129R vector (for G129R conditioned media) were cultured in 12 ml culture media
without zeocin for 72 hours, then collected, centrifuged at 1000 g for 15 minutes, passed
through a 0.22 μm filter and stored at -80℃ until use.
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Western blot
For cell samples, cells were harvested and lysed with RIPA buffer (150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH8.0) in the ratio of 1
million cells with 200 μl RIPA buffer. The conditioned media samples were directly used
or diluted with fresh completed media to the desired concentrations. All the samples were
mixed with protease inhibitor cocktail (Cell Signaling Technology, #5871) with a final
concentration of 1% and loading buffer (10% SDS, 500mM DTT, 50% Glycerol, 250mM
Tris-HCL and 0.5% bromophenol blue dye, PH6.8) with a final concentration of 20%, and
then boiled for 10 minutes. The proteins in the samples were separated by SDS-PAGE
(10% or 12% polyacrylamide gels) and then transferred onto 0.45 μm pore-size
nitrocellulose membranes (Bio-Rad). The membranes were blocked with 5% non-fat dry
milk in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween-20) overnight. The
proteins were detected with the primary antibodies followed by secondary antibodies
conjugated with horseradish peroxidase (HRP). Blots were developed using enhanced
chemiluminescence (ECL) detection reagents (ThermoFisher, 32209) and exposed to
X‑ray films. The films were scanned and quantified using ImageJ (National Institutes of
Health). All the antibodies used in this study were listed in Table 3.2.
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Table 3.2 Antibodies used in this study
Antibody

Host

Reactivity

Catalog#

Company

Primary

MICA

Mouse

Human

sc-137242

Santa Cruz

Primary

PRL

Mouse

Human

sc-46698

Santa Cruz

Primary

PRLR

Mouse

Human

sc-377098

Santa Cruz

Primary

V5

Mouse

--

#80076

Cell Signaling

Secondary

mIgG BP-HRP

--

Mouse

sc-516102

Santa Cruz

Secondary

anti-Mouse IgG
(H+L)_Alexa Fluor
488
anti-Mouse IgG
(H+L)_Alexa Fluor
594

Chicken

Mouse

A-21200

ThermoFisher

Chicken

Mouse

A-21201

ThermoFisher

Secondary

Immunofluorescent staining
To investigate the binding of the MICA-G129R fusion protein to T-47D cells, two
hundred thousand T-47D cells were seeded on two glass coverslips in two 35 mm dishes
with culture media and cultured overnight. After the media was removed, one coverslip
was covered with control conditioned media, and the other one was covered with MICAG129R conditioned media. After incubation for 2 hours, the slides were washed with PBS,
fixed with 4% formaldehyde, blocked with 1% BSA for 30 minutes, incubated with mouse
anti-human MICA (Santa Cruz Biotechnology, sc-137242) primary antibody for one hour,
and incubated with chicken anti-mouse IgG secondary antibody conjugated with Alexa
Fluor 488 (ThermoFisher, A-21200) for one hour. After wash, the slides were mounted
using mounting buffer with DAPI and observed with a fluorescence microscope (LEICA
DMi8).
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To stain the ectopically expressed PRLR in HEK293 cells, the cells of untransfected
HEK293 and HEK293 PRLR stable clone respectively were seeded on glass coverslip in
35 mm dish and incubated overnight. After removal of the media, the cells with the
coverslip were washed with PBS, fixed with 4% formaldehyde, blocked with 1% BAS for
one hour, incubated with anti-PRLR primary antibody for one hour and then incubated
with chicken anti-mouse secondary antibody conjugated with Alexa Fluor 594
(ThermoFisher, A-11005) for on hour. After rinse, the slides were mounted with mounting
buffer containing DAPI and observed with a fluorescence microscope.
Flow cytometry
One million of NK-92 cells were collected and equally separated into two groups.
They were incubated with control conditioned media or MICA-G129R conditioned media
at 37℃ in a 5% CO2 humidified incubator for two hours. Then the cells were respectively
collected, put on ice, washed with cold PBS, blocked with 1% BSA for 10 minutes,
incubated with mouse anti-human PRL (Santa Cruz Biotechnology, sc-46698) primary
antibody for 20 minutes, and incubated with chicken anti-mouse IgG secondary antibody
conjugated with Alexa Fluor 488 (ThermoFisher, A-21200) for 15 minutes. After three
times wash with cold PBS, the cells were pelleted and resuspended in cold PBS, and kept
on ice until analyzed with flow cytometer (BD Accuri C6).
Cytotoxicity assay
The target cells were seeded in 96-well plates and incubated at 37℃ in a 5% CO2
humidified incubator overnight. After the media was removed, 50% Alpha Minimum
Essential Medium and 50% of conditioned media with NK-92 cells at the effector/target
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ratios was added to co-cultures the cells in the 37℃, 5% CO2 humidified incubator for 24
hours. Then the plates were centrifuged at 500 g for 5 min, 50 μl of supernatant was
collected from each well for determining the cytotoxicity using the CytoTox 96
nonradioactive cytotoxicity assay (Promega, G1780) following the manufacturer’s
protocol. The assay determines the cytotoxicity by measuring the lactate dehydrogenase
(LDH), a stable cytosolic enzyme, released by the lysed cells. For each conditioned media
treatment, many control wells were set at the same time for the calculation of the
cytotoxicity: NK cells only (for effector cell spontaneous LDH release), target cells only
(target cell spontaneous LDH release), target cells with lysis solution (for target cell
maximum LDH release) and medium only (background). The cytotoxicity for each
condition was calculated using the following formula:
Cytotoxicity =

Experimental − Effector Spontaneous − Target Spontaneous
Target Maximum − Target Spontaneous

× 100%

MICA-G129R fusion protein purification

The MICA-G129R fusion protein was purified from the conditioned media using
nickel sepharose beads (Ni Sepharose™ 6 Fast Flow, GE Healthcare, 17-5318-02). Five
hundred μl of beads were mixed with 90 ml MICA-G129R conditioned media and rotated
overnight at 4℃. The slurry was applied to a column to allow the beads to pack. The
MICA-G129R conditioned media was collected after passing through the column twice.
Then the column was washed with 10 ml high salt Buffer A (20 mM K2HPO4 pH 7.5, 10%
glycerol, 0.5 mM EDTA, 0.01% IGEPAL and 1 mM DTT) containing 1 M KCl and 25
mM imidazole followed by a wash with 10 ml low salt Buffer A containing 150 mM KCl
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and 25 mM imidazole. The bound MICA-G129R protein was eluted by adding 0.5 ml of
Buffer A containing 150 mM KCl and 500 mM imidazole to the beads, incubated for 5
min, then the column was drained and the elution buffer containing MICA-G129R protein
was collected. This elution step was repeated for two more times. The three elution
fractions containing the purified MICA-G129R were pooled, passed through a 0.22 μm
filter and stored at -80℃ until use.
Coomassie Blue staining
The SDS-PAGE gel was stained with Coomassie Blue solution (0.1% Coomassie
Blue R250 in 10% acetic acid, 50% methanol and 40% H2O) and shook for one hours.
Then the gel was exposed to destain solution (10% acetic acid, 50% methanol and 40%
H2O) and shook for four hours. Changed the destain solution twice during the destaining.
High-performance liquid chromatography (HPLC)
The MICA-G129R conditioned media and the purified MICA-G129R protein
solution were diluted with PBS at 1:20 and 1:5 ratios, and then analyzed using reversedphase HPLC. Polypropylene trilobal capillary-channeled polymer (C‐CP) fibers were
packed as the HPLC column as previously described [134]. The separation procedures were
carried out following a method built previously [135].
Protein quantification
The proteins in the purified MICA-G129R solution were quantified using Pierce
BCA Protein Assay (ThermoFisher Scientific, 23227) according to the manufacture’s
introduction. The provided albumin (BSA) in the assay was made serial dilutions as the
protein standards.
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ELISA
To check the release of granzyme B and IFN-γ of NK-92 cells, NK-92 cells were
cultured only or with T-47D cells at the ratio of 1:1, and the purified MICA-G129R protein
at the final concentration of 125 nM (equivalent to the MICA-G129R concentration in the
mixed media with 50% MICA-G129R conditioned media we used in the cytotoxicity
assays) or the elution buffer in the protein purification as control were added. After 6 hours
incubation and a quick spin, the supernatant was collected for ELISA. Human granzyme B
ELISA kit (B&D Systems, DY2906-05) and Human IFN-γ uncoated ELISA kit
(Invitrogen, 88-7316) were used for the ELISA measurements according to the
manufacture’s protocols.
Caspase-3 activity measurement
T-47D cells only or co-cultured with NK-92 cells at the ratio of 1:1 were cultured
with the purified MICA-G129R protein at the final concentration of 125 nM or the elution
buffer from the protein purification as control for 6 hours. After removal of the media or
media with NK-92 cells, the T-47D cells of each treatment were washed with PBS, lysed
and collected. The total proteins in the cell lysate of each sample were measured using
BCA assay. The same amount of total proteins from each sample was used for detecting
the caspase-3 activity using the Capspase-3 fluorometric kit (R&D Systems, BF1100)
according to the manufacture’s instruction.
Statistical analysis
In all the experiments, each treatment was performed in three replicates unless
otherwise indicated and the experiments were repeated at least twice. The results were
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expressed as the mean ± standard deviation (SD). The significant differences were
evaluated using either two-tailed Student’s t-test (for comparisons between two groups) or
one-way analysis of variance (ANOVA) (for comparisons between three or more groups)
and then Tukey’s HSD test. P < 0.05 was considered to indicate a statistically significant
difference.
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CHAPTER FOUR
RESULTS

4.1 Generation of MICA-G129R fusion protein and MICA, G129R control proteins
The MICA-G129R fusion protein was designed to fuse the extracellular domain of
MICA and the PRL mutant G129R without the signal peptide with a linker sequence to
provide flexibility (Figure 4.1). A V5-tag was added for the detection of the protein and a
His-tag was included for assisting purification of the protein.
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Figure 4.1 Schematic diagram of MICA-G129R fusion protein. Made from Protein
Data Bank: 1HYR (for MICA) and 1RW5 for (PRL/G129R).

4.1.1

Construction of expression vectors of MICA-G129R, MICA and G129R
The gene sequences of the extracellular domain of MICA and G129R without the

signal peptide were cloned and inserted into the mammalian expression vector
pcDNA3.1/Zeo(+). A (GGGS)×3 linker sequence was used to hinge the MICA and G129R.
A V5 tag and a His tag were aligned downstream of the MICA and G129R segments in the

43

open reading frame in the vector (Figure 4.2A). The DNA sequence of the fusion gene and
the amino acid sequence of the fusion protein were attached in the Appendices A. The gene
sequence of the extracellular domain of MICA or the gene sequence of the G129R with the
signal peptide were also cloned and inserted respectively into the vector pcDNA3.1/Zeo(+)
as the MICA vector or G129R vector (Figure 4.2B, C). All the insertions and junctions
within the vectors were confirmed by sequencing. There are signal peptides at the Nterminus of both the MICA and G129R which will lead the MICA and G129R to be
secreted outside of the cells. The signal peptide of MICA was kept in the MICA-G129R
fusion protein and would lead it to be secreted by the transfected cells. All the MICAG129R, MICA, G129R in the vectors are driven by CMV promtor. And there is a zeocinresistant gene in the vector to assist selection of the transfected mammalian cells from the
untransfected ones.
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Figure 4.2 Expression vectors of MICA-G129R, MICA and G129R. (A) The MICAG129R vector containing the extracellular domain of MICA, the G129R without the signal
peptide, the V5-tag and the His-tag. (B) The MICA vector containing the extracellular
domain of MICA. (C) The G129R vector containing the G129R with the signal peptide.
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4.1.2

Expression of MICA-G129R in HEK293 cells
The pcDNA3.1/Zeo(+)_MICA-G129R vector was transfected into HEK293 cells.

Zeocin was used to select the cells transfected by the vector. After selection, three HEK293
cell clones was picked for expansion. The proteins in the cell lysates from these three clones
were detected for the MICA-G129R fusion protein using anti-MICA antibody in Western
blot. The untransfected HEK293 cells were used as control. A band showed in each of the
three clones, which could be the MICA-G129R fusion protein expressed by the transfected
cells (Figure 4.3A). The band in clone 2 was the strongest in all the three bands, so it was
used for the further confirmation of the MICA-G129R fusion protein. Three antibodies,
anti-MICA, anti-PRL (for G129R) and anti-V5 were used in Western blot to identify the
protein in the clone 2. At the same protein size, positive bands were exhibited in the
Western blots of all the three antibodies (Figure 4.3B). It demonstrated that MICA-G129R
fusion protein was successfully expressed by the HEK293 stable clone 2.

46

Figure 4.3 Expression of MICA-G129R fusion protein in HEK293 cells. HEK293 cells
were transfected with vector pcDNA3.1/Zeo(+)_MICA-G129R, and then three stable
clones were picked with zeocin selection. (A) The expression level of MICA-G129R fusion
protein in three HEK293 stable clones was detected using anti-MICA in Western blot. (B)
The MICA-G129R fusion protein in the HEK293 stable clone 2 was detected using antiMICA, anti-PRL (for G129R) and anti-V5 antibodies. GAPDH was used as the internal
control.
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4.1.3

MICA-G129R fusion protein conditioned media
To verify if MICA-G129R fusion protein is successfully secreted into the media as

expected, the conditioned media was collected from the pcDNA3.1/Zeo(+)_MICA-G129R
transfected HEK293 stable clone 2 after 3-day culture, and detected using anti-MICA, antiPRL and anti-V5 antibodies, and all the antibodies detected positive protein at the same
size. So, the MICA-G129R fusion protein was confirmed to be secreted into the
conditioned media (Figure 4.4). In addition, we collected the culture media from day 0 to
day 5 and measured the MICA-G129R protein in them using anti-MICA antibody in
Western blot. We found that the MICA-G129R fusion protein was linearly produced and
accumulated in the culture media during the five days (Figure 4.5). On average, the fusion
protein increased 70.1% every day in the conditioned media. In the fifth day, the fusion
protein was accumulated to be 3.55 times of its amount in the first day. Considering the
accumulation of cellular waste and the depletion of the nutrients in the media, we did not
conduct a longer culture. And we collected the 72-hour MICA-G129R conditioned media
in a controlled cell number and media volume condition for the further investigation.
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Figure 4.4 MICA-G129R fusion protein was verified in the conditioned media. The
conditioned media from pcDNA3.1/Zeo(+)_MICA-G129R transfected HEK293 stable
clone 2 was detected using anti-MICA, anti-PRL and anti-V5 antibodies in Western blot.
The conditioned media from untransfected HEK293 cells was used as control. All the
conditioned media were collected after 3-day culture with the cells.
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Figure 4.5 MICA-G129R fusion protein was accumulated in the conditioned media.
(A) The conditioned media from pcDNA3.1/Zeo(+)_MICA-G129R transfected HEK293
stable clone 2 were detected from day 0 to day 5, and detected using anti-MICA in Western
blot. (B) The qualification of the Western blot in (A). All the MICA-G129R protein levels
were normalized to the MICA-G129R protein level of day 1.
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4.1.4

Expression of MICA and G129R control proteins
The pcDNA3.1/Zeo(+)_MICA and pcDNA3.1/Zeo(+)_G129R expression vectors

were also respectively transfected into HEK293 cells. Through zeocin selection, stable
clones were established. The expression of MICA and G129R proteins were first confirmed
to be expressed inside the cells of the stable clones by Western blot. Then the conditioned
media from the stable clones were collected for confirming that they were also secreted
into the media (Figure 4.6). The most productive stable clones were used for producing the
MICA or G129R conditioned media used in the subsequent studies.

Figure 4.6 Expression of MICA and G129R proteins in conditioned media. The MICA
and G129R expression vector were respectively transfected into HEK293 cells and the
stable clones were selected. The MICA protein (A) and the G129R protein (B) in the
respective conditioned media were detected using Western blot beside the MICA-G129R
conditioned media.
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4.2 MICA-G129R bound to T-47D cells and NK-92 cells
4.2.1

MICA-G129R bound to T-47D cells
To check if the MICA-G129R fusion protein can bind to breast cancer cells, the

MICA-G129R conditioned media were investigated by adding into the cell culture of T47D cells that are a PRLR-positive breast cancer cell line. The conditioned media from
untransfected HEK293 cells were used as control. After incubation, the cells were detected
with mouse anti-MICA primary antibody and then anti-mouse secondary antibody
conjugated with Alexa Fluor 488. The T-47D cells incubated with MICA-G129R
conditioned media were observed to be Alexa Fluor 488-positive and exhibited fluorescent
green while the cells with the control conditioned media were not (Figure 4.7). DAPI
stained the nuclei and showed all the cells. The result demonstrates that the MICA-G129R
protein in the conditioned media bound to the T-47D cells so that the T-47D cells could be
fluorescently stained by the antibodies.
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Figure 4.7 MICA-G129R fusion protein bound to T-47D cells. Control or MICAG129R conditioned media were incubated with T-47D cells for two hours. Then the T-47D
cells were fixed and first incubated with anti-MICA(m) primary antibody then with antimIgG Alexa Fluor 488 secondary antibody and DAPI. After that, the T-47D cells were
observed under fluorescence microscope.

4.2.2

MICA-G129R bound to NK-92 cells
A human NK cell line, NK-92, was also incubated with the control and MICA-

G129R conditioned media, followed by incubation with mouse anti-PRL primary antibody
and then incubation with anti-mouse secondary antibody conjugated with Alexa Fluor 488.
Finally, the NK-92 cells were analyzed using flow cytometry. We found that the curve of
NK-92 cells incubated with the MICA-G129R conditioned media shifted to the right
compared to NK-92 cells incubated with the control conditioned media, which means there
are more NK-92 cells stained fluorescent green when incubated with MICA-G129R
conditioned media, demonstrating that the MICA-G129R protein also bound to NK-92
cells (Figure 4.8).
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Figure 4.8 MICA-G129R fusion protein bound to NK-92 cells. Control or MICAG129R conditioned media were incubated with NK-92 cells for two hours. Then the NK92 cells without fixation were incubated with anti-PRL(m) primary antibody and then with
anti-mIgG Alexa Fluor 488 secondary antibody. After that, the NK-92 cells were analyzed
using flow cytometer. FL1 indicates the 530/30 nm standard interference filter.

4.3 MICA-G129R enhanced cytotoxicity of NK-92 cells on PRLR-positive cells
4.3.1

MICA-G129R enhanced cytotoxicity at different target/effector ratios
We hypothesize that the MICA-G129R bridges NK cells and breast cancer cells

and activate the cytotoxicity of NK cells to breast cancer cells. To quickly investigate this
hypothesis, we used the MICA-G129R conditioned media to test the fusion protein in the
co-culture of NK-92 cells and T-47D cells. NK-92 cells and T-47D cells were at 5:1, 2:1,
1:1, and 1:2 effector/target ratios and incubated with MICA-G129R conditioned media or
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control conditioned media for 24 hours. Then the supernatant of the culture was collected
to detect and quantify lactate dehydrogenase (LDH) released by the cells upon plasma
membrane damage for determination of the target cells death or cytotoxicity. The MICAG129R conditioned media induced 60.8% target cell death at the 5:1 effector/target ratio
while control conditioned media only induced 39.8% target cell death (P = 0.003) (Figure
4.9). The T-47D cell deaths with control or MICA-G129R conditioned media were 17.9%
vs. 39.2% (P = 0.007) at 2:1 effector/target ratio, 5.9% vs. 20.8% (P = 0.021) at 1:1
effector/target ratio, and 0% vs.12.9% (P = 0.020) at 1:2 effector/target ratio. All the target
cell deaths were significantly increased by the MICA-G129R conditioned media.
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Figure 4.9 MICA-G129R fusion protein enhanced the cytotoxicity of NK-92 cells on
T-47D cells at different effector/target ratios. PRLR-positive breast cancer cells T-47D
were co-cultured with NK-92 cells at 5:1, 2:1, 1:1 and 1:2 effector/target ratios for 24 hours
with control or MICA-G129R conditioned media. Then the T-47D cell death were
measured using LDH based cytotoxicity assay. Data are presented as mean ± SD (n = 3).
* indicates P<0.05; ** indicates P<0.01.
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4.3.2

MICA or G129R failed to enhance cytotoxicity
To investigate if the MICA only or the G129R only proteins can also enhance the

T-47D cell death in the co-culture, the MICA conditioned media and separately the G129R
conditioned media were added into the co-culture of NK-92 and T-47D cells at the 1:1
effector/target ratio. The result revealed that those conditioned media failed to significantly
enhance the cytotoxicity of NK-92 cell on T-47D cells as observed with the MICA-G129R
conditioned media (Figure 4.10). The MICA-G129R conditioned media induced 18.9% of
the T-47D cell death, while MICA conditioned media induced 5.8% and G129R
conditioned media induced 1.5%. The MICA conditioned media induced a little more
target cell death than the control conditioned media without statistically significance.

Figure 4.10 MICA and G129R protein failed to enhance the cytotoxicity of NK-92
cells on T-47D cells. T-47D cells were co-cultured with NK-92 cells at 1:1 effector/target
ratio for 24 hours with control, MICA-G129R, MICA or G129R conditioned media. Then
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the T-47D cell death were measured using LDH based cytotoxicity assay. Data are
presented as mean ± SD (n = 3). ** indicates P<0.01.

4.3.3

MICA-G129R enhanced cytotoxicity targeting PRLR-positive cells
The G129R portion of the MICA-G129R fusion protein targets the PRLR on the

cells. To confirm that PRLR on the target cells is necessary for the MICA-G129R protein
to enhance the cytotoxicity, we used HeLa cells that were derived from cervical cancer
cells as the negative control. We first confirmed that HeLa cells do not express PRLR
(Figure 4.11A) and co-cultured HeLa cells with NK-92 cells in control or MICA-G129R
conditioned media to investigate the cytotoxicity. The result indicated that the MICAG129R conditioned media could not promote the cytotoxicity of NK cells on HeLa cells
(Figure 4.11B).

Figure 4.11 MICA-G129R fusion protein cannot promote the cytotoxicity of NK-92
cells on PRLR-negative HeLa cells. (A) HeLa cells were confirmed not expression PRLR
by Western blot. (B) HeLa cells and T-47D cells were respectively co-cultured with NK92 cells at 1:1 effector/target ratio for 24 hours with control or MICA-G129R conditioned
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media. Then the cell death was measured using LDH based cytotoxicity assay. Data are
presented as mean ± SD (n = 3). ** indicates P<0.01.
To investigate if ectopic expression of PRLR in PRLR-negative cells can increase
the cytotoxicity mediated by MICA-G129R, we transfected a PRLR expression vector into
HEK293 cells that are PRLR-negative. We established three stable PRLR clones (Figure
4.12A). The clone 2 expressed the most PRLR. We stained the cells of PRLR clone 2 with
anti-PRLR primary antibody and fluorescent compound Alexa Fluor 594 conjugated
secondary antibody and confirmed that PRLR was highly expressed in the HEK293 cells
(Figure 4.12B). Then the untransfected HEK293 cells and PRLR clone 2 (HEK293_PRLR)
were co-cultured with NK-92 cells in control or MICA-G129R conditioned media to
investigate their difference in cell death. We found that there were significantly more
HEK293_PRLR cells killed in the MICA-G129R conditioned media compared to them in
the control conditioned media (17.0% vs. 0.8%, P = 0.002) (Figure 4.13). There were also
more HEK293 cells killed in the MICA-G129R conditioned media compared to HEK293
cells in the control conditioned media but not statistically significant (4.9% vs. 0.8%, P =
0.071).
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Figure 4.12 PRLR was ectopically expressed in HEK293 cells. (A) An expression vector
with PRLR was transfected into HEK293 cells. Three stable clones were established and
examined for the PRLR expression using Western blot. (B) HEK293 PRLR stable clone 2
were stained using anti-PRLR primary antibody and Alexa Fluor 594 conjugated secondary
antibody, and DAPI.
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Figure 4.13 MICA-G129R fusion protein promoted cytotoxicity of NK-92 cells on
PRLR ectopically expressed HEK293 cells. The untransfected HEK293 cells and
HEK293 PRLR stable clone 2 (HEK293_PRLR) were respectively co-cultured with NK92 cells at 1:1 effector/target ratio for 24 hours with control or MICA-G129R conditioned
media. Then the cell death was measured using LDH based cytotoxicity assay. Data are
presented as mean ± SD (n = 3). ** indicates P<0.01.
4.4

Purification of MICA-G129R fusion protein

4.4.1

MICA-G129R protein purification
The MICA-G129R protein was designed with a His tag to help its purification and

concentration. We used the nickel resin chromatography to bind and purified the MICAG129R protein from the conditioned media. The fractions in the purification including the
flow-through, wash buffer and three elution solutions were analyzed using Western blot
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with the unpurified conditioned media as control (Figure 4.14). It is very clear that the first
elution contained the most fusion protein. The second elution contained the MICA-G129R
protein at the comparable level with the original conditioned media while the third elution
contained almost no MICA-G129R fusion protein. And after the purification, there was
much few MICA-G129R fusion protein left in the flow-through fraction. We used the first
elution as the purified MICA-G129R fusion protein for the following studies.

Figure 4.14 Western blot analysis of the fractions in MICA-G129R purification. The
MICA-G129R conditioned media were passed through nickel sepharose beads column for
purifying the MICA-G129R fusion protein. The original MICA-G129R conditioned media,
flow-through, wash buffer and three elution solutions were analyzed using anti-MICA in
Western blot.
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4.4.2

Quantification analysis of the purified MICA-G129R
To analyze the purity of the MICA-G129R fusion protein, we run the purification

elution in a protein gel and visualized the total proteins with Coomassie Blue (Figure
4.15A). The biggest band in the elution indicated by the white arrow is MICA-G129R. The
other light bands are the impurities which are relatively minor. There are many proteins
found in the unpurified conditioned media and it is hard to distinguish which band is the
MICA-G129R fusion protein. We also analyzed the purified and unpurified MICA-G129R
using revered-phase HPLC on the C-CP fiber column [134,135]. For the purified MICAG129R, the peak representing MICA-G129R (indicated with the white arrow in Figure
4.15B) accounts for 70.0% of the total area under the curve, which means the purity of
MICA-G129R in the total protein is 70.0%. The other peaks were dampened or disappeared
after the purification reflecting that most of other proteins in the conditioned media were
removed in the purification.
By BCA assay, the total proteins in the purified solution was determined to be
1007.5 ± 10.0 μg/ml. As 70.0% of the total proteins is MICA-G129R, the concentration of
MICA-G129R protein is 705.3 μg/ml. Based on the amino acid sequence, the molecular
weight of the MICA-G129R fusion protein (including the V5 tag and His tag, without the
signal peptide) was calculated to be 59.2 kDa using an online bioinformatic tool
(https://www.bioinformatics.org/sms/prot_mw.html). Therefore, the molar concentration
of MICA-G129R protein in the purified solution was 11.9 μM.
To further quantify the MICA-G129R protein in the purified solution, we
performed serial dilutions of the purified solution and analyzed the MICA-G129R in the
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dilutions using Western blot (Figure 4.16). We detected and quantified the MICA-G129R
protein in the dilution, and performed regression analysis. The all the dilutions fit a
regression line (logarithmic) very well. From it, we could determine that the concentration
of MICA-G129R protein in the purified solution was 47.6 times more concentrated than
the MICA-G129R protein in the original conditioned media. By further calculation, we
found out that the MICA-G129R protein in the conditioned media was 14.8 μg/ml (250.0
nM). As the volume of the MICA-G129R conditioned media was decreased 60-fold in this
purification, the recovery of the MICA-G129R protein in the purification was 79.3%.
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Figure 4.15 Coomassie blue staining and HPLC analysis of purified MICA-G129R.
(A) Coomassie blue stained protein gel with MICA-G129R conditioned media and purified
MICA-G129R. CM indicates the lane with the MICA-G129R conditioned media before
purification. M indicates the lanes with the protein standard marker. P indicates the lanes
with the purified MICA-G129R protein solution. The loading volume of each sample was
also indicated above each lane. The white arrow indicates the bands of MICA-G129R. (B)
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HPLC analysis of the MICA-G129R conditioned media and the purified MICA-G129R
protein solution. The white arrow indicates the peaks of the MICA-G129R protein.

Figure 4.16 Quantification analysis of purified MICA-G129R. (A) The MICA-G129R
fusion proteins in the conditioned media and the serial dilutions of the purified protein were
detected using anti-MICA in Western blot. The purified MICA-G129R was diluted with
fresh culture media of HEK293 cells. CM indicates the lane with the MICA-G129R
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conditioned media before purification. The numbers on the lanes indicate the dilution
factors. (B) Quantification of the MICA-G129R protein bands in (A). All the bands were
quantified based on the average relative densities using ImageJ. The serial dilutions of the
purified MICA-G129R protein solution were quantified and modeled by a regression line
(logarithmic). The red dot shows where the original MICA-G129R conditioned media is
on the regression line based on its average relative density.

4.4.3

Purified MICA-G129R fusion protein enhanced cytotoxicity
To test if the purified MICA-G129R fusion protein can induce cytotoxicity as the

conditioned media, we added the purified MICA-G129R protein to the co-culture of NK92 cells and T-47D cells at the same MICA-G129R protein level as it in the conditioned
media. The elution buffer in the purification was used as control. The purified MICAG129R fusion protein significantly increased the target cells death to 21.1% after 24 hours
incubation (Figure 4.17). It is comparable with the MICA-G129R which induced 20.8%
target cell death.
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Figure 4.17 Purified MICA-G129R fusion protein enhanced cytotoxicity. T-47D cells
were co-cultured with NK-92 cells at 1:1 effector/target ratio for 24 hours with control
(elution buffer) or the purified MICA-G129R at the same MICA-G129R protein level as it
in the conditioned media. Then the T-47D cell death were measured using LDH based
cytotoxicity assay. Data are presented as mean ± SD (n = 3). *** indicates P<0.001.

4.5 MICA-G129R activated NK-92 cells
4.5.1

MICA-G129R activated NK-92 cells to release granzyme B and IFN-γ
To check if MICA-G129R fusion protein activate NK-92 cells, we investigated the

levels of the granzyme B and IFN-γ released by NK-92 in the co-culture of NK-92 cells
and T-47D cells or the culture of NK-92 cells only with or without the purified MICAG129R fusion protein. The elution buffer in the protein purification was used as control.
The results revealed that no matter NK-92 cells cultured with or without T-47D cells,
MICA-G129R fusion protein significantly increased granzyme B and IFN-γ released by
NK-92 cells. When there was no MICA-G129R protein, co-culture with T-47D cells could

68

significantly elevate both granzyme B and IFN-γ released by NK-92 cells. When adding
MICA-G129R fusion protein, co-cultured with T-47D cells could also promote NK-92
cells to release IFN-γ but could not increase the granzyme B level anymore. To add MICAG129R protein and to add T-47D cells could achieve same level of IFN-γ releasing. To add
MICA-G129R protein even induced higher level of granzyme B release than to add T-47D
cells (Figure 4.18).
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Figure 4.18 MICA-G129R fusion protein activated NK-92 cells to release granzyme
B and IFN-γ. Co-culture of NK-92 cells and T-47D cells at the ratio 1:1 or NK-92 cells
only were cultured in the media with or without the purified MICA-G129R protein. After
6 hours, the media were collected for (A) ELISA of granzyme B or (B) ELISA of IFN-γ.
Data are presented as mean ± SD (n = 3). ** indicates p < 0.01; *** indicates p < 0.001.
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4.5.2

MICA-G129R induced apoptosis of T-47D cells in co-culture with NK-92
To investigate if T-47D cells were induced into apoptosis, we investigated the

activity levels of caspase-3 in the T-47D cells in co-culture with NK-92 cells or cultured
alone using a fluorometric assay. In the result, when there were no NK-92 cells, the
caspase-3 activity in T-47D cells was at a very low level. The MICA-G129R fusion protein
could not induce any remarkable difference, so there was no detectable apoptosis. In the
co-culture, NK-92 cells induced the caspase-3 activity in the T-47D cells to a relative high
level, which suggested NK-92 cells induced apoptosis of T-47D cell. The MICA-G129R
fusion protein further elevated the level of caspase-3 activity in the T-47D cells of the coculture (Figure 4.19).
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Figure 4.19 MICA-G129R induced apoptosis of T-47D cells in co-culture with NK-92.
Co-culture of NK-92 cells and T-47D cells at the ratio 1:1 or T-47D cell only were cultured
in the media with or without the purified MICA-G129R protein. After 6 hours, the activity
of caspase-3 in T-47D cells from the co-culture or T-47D cell only culture was measured
using the caspase-3 fluorescence assay. Data are presented as mean ± SD (n = 3). *
indicates p < 0.05.
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CHAPTER FIVE
DISCUSSION
5.1 Summary of the results
We designed and constructed the MICA-G129R gene and expressed the MICAG129R fusion protein using HEK293 cells. We confirmed the fusion protein’s integrity
and secretion into the media. By using MICA-G129R conditioned media, we demonstrated
that the MICA-G129R fusion protein could bind to PRLR-positive breast cancer T-47D
cells and NK-92 cells. At different effector/target cell ratios, MICA-G129R all could
significantly enhance the cytotoxicity of NK cells on T-47D cells. Compared with MICAG129R fusion protein, the MICA protein alone or the G129R protein alone could not
significantly promote the cytotoxicity, suggesting that the bridge between the effector cells
and target cells by the fusion protein is necessary to the cytotoxicity. In addition, by
comparing T-47D cells with the PRLR-negative HeLa cells and comparing HEK293 cells
with PRLR ectopically expressed HEK293 cells in the co-culture with NK-92 cells, it could
be concluded that PRLR on the target cells is necessary for the killing.
We purified the MICA-G129R fusion protein from the conditioned media, and
quantitatively analyzed the fusion protein. We recovered 79.3% of the MICA-G129R
fusion protein from the conditioned media and concentrated the fusion protein 47.6 times
in the purification with 70% purity. When testing the purified protein in co-culture, it
induced the same level of cell death of T-47D cells as the conditioned media. It was also
demonstrated that the MICA-G129R fusion protein could promote NK-92 cells to release
granzyme B and IFN-γ that are two of the major effector factors in cytotoxicity. The

73

caspase-3 activity in the T-47D cells in the co-culture with NK-92 cells was also found to
be higher when with the fusion protein than without the fusion protein, which further
supported that MICA-G129R enhanced the cytotoxicity.
5.2 MICA-G129R fusion protein
5.2.1

MICA-G129R design
The MICA-G129R fusion protein we developed is different from most of other

bispecific proteins that use antibodies for targeting. We used the G129R to specifically
target the PRLR on breast cancer cells. G129R is an antagonistic mutant of PRL and can
block the activity of the PRL/PRLR axis. Itself was reported to be able to induce apoptosis
of breast cancer cells and prolonged treatment with G129R induced autophagy-related cells
death [21,22]. So, G129R can target and intrinsically suppress breast cancer cells.
The MICA portion targets to NKG2D that is a the activating receptor not only
expressed on NK cells, but also expressed on NKT cells, CD8+ T cells, γδ T cells, and some
activated CD4+ T cells [136]. Therefore, MICA-G129R can stimulate all these immune
cells resulting in a range of immune effector functions, such as cytotoxicity and cytokine
production to eliminate target cancer cells.
G129R as a variant of PRL, even with a signal amino acid substitution mutation, is
very similar to PRL; the MICA portion is the extracellular domain of MICA, a part of a
natural protein in the body, which make MICA-G129R less likely to induce immune
problem itself compared with other fusion proteins.
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5.2.2

MICA-G129R purification
The MICA-G129R fusion protein was designed to be a secretory protein that is

easier to be collected than cytoplasmic protein. Our results revealed that the MICA-G129R
fusion protein was greatly produced and secreted into the media. In addition, there is a His
tag on the protein to assist its purification through the interaction between the sidechains
of the histidine residues and the chelated transition metal ions in the immobilized metal ion
affinity chromatography. Our purification achieved a great recovery and purity of the
MICA-G129R fusion protein.
The reasons for that we first used the conditioned media with the fusion protein
MICA-G129R instead of directly using purified protein are that the fusion protein in the
conditioned media is considered to be good enough for the quick concept-confirmation
study, and that the control proteins MICA only and G129R only were both expressed in
conditioned media without affinity tags for purification with consideration of minimizing
the unknown influence on their binding. After the feasible confirmation of the fusion
protein and comparison with the two control proteins, we purified the fusion protein and
quantification of the fusion protein. We conducted Coomassie staining and HPLC analysis
to visualize and quantify the MICA-G129R protein after purification. We also diluted the
purified MICA-G129R protein and compared the serial dilutions with the MICA-G129R
in the conditioned media before purification. The purified protein induced the same level
of cytotoxicity in the co-culture as the MICA-G129R conditioned media. These analyses
connected the studies before and after the purification.
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5.2.3

Shedding of MICA
Advanced cancer cells were reported to shed MICA to evade NKG2D-mediated

immune detection and elimination. The shedding was reported by the metalloproteases
ADAM10 and ADAM17, and the proteolytic cleavage sites are in the stalk of the MICA
ectodomain [128]. When designed our MICA-G129R fusion protein, we have removed the
cleavage sites. The fusion protein will adhere the MICA back to the surface of breast cancer
cells through the binding of the G129R to PRLR.
The shed MICA is released into the circulation and becomes sMICA which was
also reported to be correlated with the NKG2D downregulation [130]. The MICA-G129R
fusion protein is also soluble but we did not find it causes the downregulation of NKG2D
but activates NKG2D. Even if the NKG2D is downregulation, it can be easily overcome
by blocking TGF-β [131] or utilizing IL-2 and IL-18 [132].
Another concern is that sMICA may compete with MICA-G129R to bind the
NKG2D on NK cells. The competition is concentration dependent. When MICA-G129R
fusion protein circulates into breast tumor, it will bind to breast cancer cells and become
immobilized, just like the MICA expressed on cancer cell surface. As more and more
fusion proteins are enriched there, sMICA will become weaker and weaker in the
competition, and the fusion protein will attract and activate NK cells and other effector
cells into the tumor. Of course, further in vivo studies are needed to better understand
whether the tumor-mediated sMICA will reduce the efficacy of MICA-G129R.
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5.3 Future Directions
5.3.1 Improvement of MICA-G129R fusion protein
Only the α1 and α2 domains of MICA provide the binding site for the NKG2D, so
the α3 domain of the MICA in the MICA-G129R fusion protein might be removed in the
future.
The affinity of the fusion protein to NKG2D can be improved. One way is to
engineer the α1 and α2 domains of MICA to improve the affinity. The other way is to
consider replacing MICA with other NKG2D ligands. NKG2D shows different affinities
for its ligands (Table 5.1) [113]. The murine ligand Mult1 displays the highest affinity for
NKG2D (Affinity KD = 0.004 µM) which is 125 time of the affinity of MICA (Affinity KD
= 0.5 µM). So, Mult1 may be a good candidate, but its immunogenicity in human body
needs to be considered because it is murine-derived.
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Table 5.1 Affinity of NKG2D and other immunoreceptors

(Spear et al. Cancer Immun. 2013)

5.3.2 In vivo study
We will use mouse model to investigate the efficacy of MICA-G129R fusion
protein in vivo. Because MICA also binds to mouse NKG2D and activates mouse NK cells
[114], we will use common mouse stain, like C57BL/6, to create a T-47D xenograft model.
We will also consider a triple-negative breast cancer cell line with PRLR expression to
generate the human breast cancer xenograft mouse model.
Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice can be
used for study the combination of MICA-G129R fusion protein and human NK cell
transfer. The NOD/SCID mice do not have T cells, B cells. Some strain (NSG, The Jackson
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Laboratory) even do not have functional NK cells [137]. So, the human NK cells, like NK92 cells, can be transfer into the mice without interaction from the immune system of the
mice. The human breast cancer xenograft model will be created in NOD/SCID mice as the
target. In this way, we can directly study if the MICA-G129R fusion protein can induce
cytotoxicity of human NK cells target human breast cancer in vivo.
The T-47D cells used for xenograft can be transfected with luciferase reporter gene,
so the size of the tumor can be monitored and quantified in living mice using
bioluminescence imaging [138]. The MICA-G129R fusion protein and the transferred NK
cells can also be fluorescent labeled, so their circulation in vivo can be tracked. We can
study if the MICA-G129R can target the tumor and enrich there, and if NK cells can be
induced into the tumor or tumor environment.
The dosages of the fusion protein and the number of NK cells will be optimized to
get the best efficacy. The body weights of mice will also be recorded daily and compared.
At the end, necropsy will be performed, and the tumor samples will be weighed and
collected for further tests.
5.3.3 Multi-Bit Screwdriver Platform
We are very interested in developing a platform with the MICA fusion protein and
NK cells to treat different types of cancers. Tumoral target expression heterogeneity is one
of the hallmarks of cancer and one of the obstacles in cancer immunotherapy, especially in
solid tumors, like breast cancer. It is difficult to just use one single agent to effectively cure
cancer, because drug-resistance can be very easily developed. If the well-studied
antibodies, like trastuzumab, pertuzumab (anti-HER2), matuzumab (anti-EGFR) are all
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respectively fused with MICA, these fusion proteins can be used together as a cocktail
therapy, so that many targets of cancer cells can be targeted at the same time.
The MICA portion in the fusion protein and NKG2D can both be engineered to
improve their binding specificity and affinity with each other, so that the designed NKG2D
and MICA can bind to each other and no longer bind to the natural NKG2D and NKG2D
ligands, which will make the system to be more precisely controlled. NK cells can be
derived from induced pluripotent stem cells (iPSCs) with the modifications: engineering to
express the new NKG2D, improving some receptors (like CD16) and removing the
intrinsic NKG2D and other unnecessary receptors to minimize the antigenicity. And the
engineered NK cells will be expanded to be allogenic and off-the-shelf and administered
with the MICA fusion proteins at same time as one administration. The dosage and
formulations of the MICA fusion proteins and NK cells can be well controlled by finetuning base on the cancer types and immune reactions of the patient.
This platform is like a multi-bit screwdriver. The handle of the screwdriver is the
engineered allogenous off-the-shelf NK cells. The MICA fusion proteins are the bits
targeting different “screws” on cancer cells. The MICA and NKG2D play the magnetic
parts. It will be a universal, multi-target, off-the-shelf, tailored formulation and wellcontrolled platform (Figure 5.1).
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Figure 5.1 Schematic diagram of “Multi-bit Screwdriver” platform. The handle of the
“screwdriver” is NK cells; MICA and NKG2D are the magnetic parts; the “bits” are fusion
proteins consisting of MICA and G129R or antibodies targeting different antigens on
cancer.

5.3.4 CAR-NK
We also plan to create a CAR-NK with G129R. Instead of using MICA to target
NKG2D on NK cells, we plan to directly replace the extracellular domain of NKG2D with
G129R. The intracellular and transmembrane domains of NKG2D and G129R fuse
together with a linker as the chimeric antigen receptor (CAR). In our hypothesis, the CAR
will assist NK cells targeting breast cancer cells through the engagement of G129R and
PRLR on breast cancer cells, and simultaneously the G129R portion will block the growth
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and induce apoptosis of breast cancer cells; when engaged, the CAR activates NK cells
through NKG2D portion and induces cytotoxicity to kill breast cancer cells (Figure 5.2).
Most of the studies on CAR has largely focused on CAR-T, while CAR-NK has
more advantages and greater potential in clinical application. And most CARs utilize
antibody to target antigens on cancer cells, but this CAR we designed uses G129R, a
mutated hormone to target the PRLR on breast cancer cells, which is a unique design of
CAR to our knowledge. The CAR obtains the activation signaling pathway of NK cells by
using the transmembrane and intracellular domains of NKG2D and has multiple pathways
to kill breast cancer cells, including the cytotoxicity from activated NK cells and inducing
apoptosis by G129R.
We have cloned the genes of the intracellular and transmembrane domains of
NKG2D and G129R and fused them in a lentiviral vector as the CAR gene. We will
package the gene into lentivirus and use the lentivirus to deliver the CAR gene into human
NK cells. The engineered NK cells with this unique CAR will be evaluated both in vitro
and in vivo.
This CAR-NK is expected to be further developed to be an efficacious therapy for
breast cancer and will importantly impact the field of cancer immune therapy.
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Figure 5.2 Schematic diagram of G129R CAR-NK. The extracellular domain of NKG2D
is replaced with G129R as the chimeric antigen receptor targeting PRLR on breast cancer
cells and activating NK cells.

83

CHAPTER SIX
CONCLUSION
In conclusion, we successfully created a MICA-G129R fusion protein which can
bridge NK cells and PRLR-positive breast cancer cells together, and promote the
cytotoxicity targeting PRLR-positive breast cancer cells. Our results demonstrated that the
fusion protein bound to NK-92 cells and PRLR-positive breast cancer T-47D cells and
significantly enhanced the cytotoxicity of NK-92 cells to kill T-47D cells at different
effector/target ratios. The MICA only or the G129R only proteins could not promote the
cytotoxicity. HeLa cells as PRLR-negative cancer cells were not found significantly killed
like T-47D cells in the co-culture with NK-92 cells mediated by the MICA-G129R fusion
protein. Ectopic expression of PRLR in PRLR-negative HEK293 cells increased the death
of HEK293 in the cytotoxicity mediated by MICA-G129R. The results support that the
cytotoxicity mediated by MICA-G129R fusion protein targets PRLR-positive cells. We
also found that the MICA-G129R protein activated NK cells to release the cytotoxic
molecules granzyme B and cytokine IFN-γ which play key roles in cytotoxicity, and the
cytotoxicity mediated by the MICA-G129R fusion protein triggered apoptosis in target
cells. Therefore, we confirmed a new design of bifunctional protein and it represents a new
approach for the development of breast cancer specific immunotherapy.
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Appendix A
Sequences of MICA-G129R
…GCTGGCTAGCGTTTAAACTTAagcttGAGAGGGTGGCGACGTCGGGGCCATGG
GGCTGGGCCCGGTCTTCCTGCTTCTGGCTGGCATCTTCCCTTTTGCACCTCCG
GGAGCTGCTGCTGAGCCCCACAGTCTTCGTTATAACCTCACGGTGCTGTCCTG
GGATGGATCTGTGCAGTCAGGGTTTCTCACTGAGGTACATCTGGATGGTCAG
CCCTTCCTGCGCTGTGACAGGCAGAAATGCAGGGCAAAGCCCCAGGGACAGT
GGGCAGAAGATGTCCTGGGAAATAAGACATGGGACAGAGAGACCAGAGACT
TGACAGGGAACGGAAAGGACCTCAGGATGACCCTGGCTCATATCAAGGACC
AGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGA
AGACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTC
CTCTCCCAAAACCTGGAGACTGAGGAATGGACAATGCCCCAGTCCTCCAGAG
CTCAGACCTTGGCCATGAACGTCAGGAATTTCTTGAAGGAAGATGCCATGAA
GACCAAGACACACTATCACGCTATGCATGCAGACTGCCTGCAGGAACTACGG
CGATATCTAAAATCCGGCGTAGTCCTGAGGAGAACAGTGCCCCCCATGGTGA
ATGTCACCCGCAGCGAGGCCTCAGAGGGCAACATTACCGTGACATGCAGGGC
TTCTGGCTTCTATCCCTGGAATATCACACTGAGCTGGCGTCAGGATGGGGTAT
CTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGG
AACCTACCAGACCTGGGTGGCCACCAGGATTTGCCAAGGAGAGGAGCAGAG
GTTCACCTGCTACATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCC
TCTGGGGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTggatccTTGCCCATCT
GTCCCGGCGGGGCTGCCCGATGCCAGGTGACCCTTCGAGACCTGTTTGACCG
CGCCGTCGTCCTGTCCCACTACATCCATAACCTCTCCTCAGAAATGTTCAGCG
AATTCGATAAACGGTATACCCATGGCCGGGGGTTCATTACCAAGGCCATCAA
CAGCTGCCACACTTCTTCCCTTGCCACCCCCGAAGACAAGGAGCAAGCCCAA
CAGATGAATCAAAAAGACTTTCTGAGCCTGATAGTCAGCATATTGCGATCCT
GGAATGAGCCTCTGTATCATCTGGTCACGGAAGTACGTGGTATGCAAGAAGC
CCCGGAGGCTATCCTATCCAAAGCTGTAGAGATTGAGGAGCAAACCAAACGG
CTTCTAGAGCGCATGGAGCTCATAGTCAGCCAGGTTCATCCTGAAACCAAAG
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AAAATGAGATCTACCCTGTCTGGTCGGGACTTCCATCCCTGCAGATGGCTGAT
GAAGAGTCTCGCCTTTCTGCTTATTATAACCTGCTCCACTGCCTACGCAGGGA
TTCACATAAAATCGACAATTATCTCAAGCTCCTGAAGTGCCGAATCATCCACA
ACAACAACTGCcgCTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTAAGCCTATC
CCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCATCATCA
TCATTGAGCGGCCGCTCGAGTCTAGAGGGCCC…
Sequence A-1: Sequence of MICA-G129R fusion gene in vector pcDNA/3.1Zeo(+).
The gray sequence is a segment of the MICA promotor. The red sequence is the sequence
of the extracellular domain of MICA (c.1-894). The yellow sequence is the linker sequence.
There are three nucleotides (GGG) overlapping between the MICA sequence and the linker
sequence. The blue sequence is the sequence of G129R without the signal peptide sequence
(c.85-681). The magenta sequence is the sequence of V5-tag. The green sequence is the
sequence of His-tag.
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MGLGPVFLLLAGIFPFAPPGAAAEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQP
FLRCDRQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQK
EGLHSLQEIRVCEIHEDNSTRSSQHFYYDGELFLSQNLETEEWTMPQSSRAQTLA
MNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRS
EASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTW
VATRICQGEEQRFTCYMEHSGNHSTHPVPSGGGSGGGSGGGSGSLPICPGGAARC
QVTLRDLFDRAVVLSHYIHNLSSEMFSEFDKRYTHGRGFITKAINSCHTSSLATPE
DKEQAQQMNQKDFLSLIVSILRSWNEPLYHLVTEVRGMQEAPEAILSKAVEIEEQ
TKRLLERMELIVSQVHPETKENEIYPVWSGLPSLQMADEESRLSAYYNLLHCLRR
DSHKIDNYLKLLKCRIIHNNNCRSSLEGPRFEGKPIPNPLLGLDSTRTGHHHHHH
Sequence A-2: Amino acid sequence of MICA-G129R fusion protein. The red sequence
is the sequence of the extracellular domain of MICA (p.1-298). The yellow sequence is the
linker sequence. There is one amino acid (G) overlapping between the MICA and the
linker. The blue sequence is the sequence of G129R (p.29-227) without the signal peptide
sequence. The magenta sequence is the sequence of V5-tag. The green sequence is the
sequence of His-tag.
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